0001124105 2026-06-22 2026-06-22 0001124105 1 2026-06-22 2026-06-22 shares iso4217:USD shares iso4217:USD pure S-3 S-3 Gyre Therapeutics, Inc. false Equity Common Stock, $0.001 par value per share true 30221531 5.84 176493741.04 0.0001381 24373.79 176493741.04 24373.79 0 0 24373.79 <table style="font-size: 12pt; border-spacing: 0px; border-collapse: collapse; width: 100%;"> <tr style="height: 0px; font-size: 0px;"><td style="width: 1%;"> </td><td style="width: 99%;"> </td></tr><tr style="vertical-align: top;"> <td style="padding: 0px 0pt;"> <div style="margin-bottom: 4pt;"> <span style="font-size: 10.0pt;">1.</span></div> </td> <td style="padding: 0px 5.4pt; text-align: left;"> <div style="margin-bottom: 4pt;"> <span style="font-size: 10.0pt;">Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement also covers such an indeterminate amount of shares of common stock as may become issuable to prevent dilution resulting from stock splits, stock dividends and similar events.<br/><br/> The amount registered consists of up to (i) 11,735,356 shares of Common Stock and (ii) 18,486,175 shares of Common Stock issuable upon the conversion of 3,697,235 shares of Series B Preferred Stock.<br/><br/> Estimated solely for the purpose of calculating the registration fee, based on the average of the high and low prices of the shares of common stock on the Nasdaq Capital Market on June 16, 2026 (such date being within five business days of the date that this registration statement was first filed with the Securities and Exchange Commission, in accordance with Rule 457(c) under the Securities Act).</span> </div> </td> </tr> </table> N/A 0001124105 EX-FILING FEES N/A